AHL Partners LLP raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 63.2% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 20,106 shares of the company’s stock after purchasing an additional 7,784 shares during the period. AHL Partners LLP’s holdings in IDEXX Laboratories were worth $3,245,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. D.A. Davidson & CO. lifted its position in shares of IDEXX Laboratories by 160.4% in the second quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock valued at $100,000 after acquiring an additional 385 shares in the last quarter. Sun Life Financial INC lifted its position in shares of IDEXX Laboratories by 9,085.7% in the second quarter. Sun Life Financial INC now owns 643 shares of the company’s stock valued at $104,000 after acquiring an additional 636 shares in the last quarter. Capital Advisors Ltd. LLC purchased a new stake in shares of IDEXX Laboratories in the second quarter valued at $128,000. Global X Management Co. LLC lifted its position in shares of IDEXX Laboratories by 44.6% in the first quarter. Global X Management Co. LLC now owns 1,047 shares of the company’s stock valued at $162,000 after acquiring an additional 323 shares in the last quarter. Finally, Coastline Trust Co purchased a new stake in shares of IDEXX Laboratories in the second quarter valued at $202,000. 87.64% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “AHL Partners LLP Boosts Holdings in IDEXX Laboratories, Inc. (IDXX)” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/ahl-partners-llp-boosts-holdings-in-idexx-laboratories-inc-idxx/1623387.html.

IDEXX Laboratories, Inc. (IDXX) opened at 157.33 on Wednesday. The company’s 50-day moving average price is $156.23 and its 200 day moving average price is $159.89. The stock has a market capitalization of $13.73 billion, a P/E ratio of 54.12 and a beta of 0.48. IDEXX Laboratories, Inc. has a 52-week low of $102.45 and a 52-week high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, August 1st. The company reported $0.95 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.10. The business had revenue of $508.90 million during the quarter, compared to analysts’ expectations of $502.44 million. IDEXX Laboratories had a negative return on equity of 473.46% and a net margin of 14.13%. IDEXX Laboratories’s revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.74 earnings per share. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post $3.18 earnings per share for the current year.

In other news, Chairman Jonathan W. Ayers sold 18,000 shares of the firm’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $155.22, for a total value of $2,793,960.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lawrence D. Kingsley bought 2,000 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The stock was acquired at an average cost of $151.76 per share, with a total value of $303,520.00. Following the transaction, the director now owns 3,344 shares of the company’s stock, valued at $507,485.44. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 151,734 shares of company stock valued at $23,436,626. 2.77% of the stock is currently owned by insiders.

Several brokerages have recently issued reports on IDXX. Canaccord Genuity restated a “buy” rating and issued a $180.00 price objective on shares of IDEXX Laboratories in a research report on Friday, October 6th. Bank of America Corporation upgraded IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price objective on the stock in a research report on Wednesday, August 23rd. Stifel Nicolaus restated a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a research report on Monday, August 21st. BidaskClub downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Finally, CL King upgraded IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price objective on the stock in a research report on Friday, July 28th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $174.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.